Health
Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study – News-Medical.Net
A team of scientists from Japan has recently investigated the neutralizing potency of convalescent sera against currently circulating SARS-CoV-2 variants with multiple…
A team of scientists from Japan has recently investigated the neutralizing potency of convalescent sera against currently circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with multiple spike mutations.
The study’s findings reveal that the variants containing Y543F or N501Y spike mutations are capable of evading neutralization by SARS-CoV-2-induced antibodies. However, no such immune evading potency has been observed for the variants with only the E484K spike mutation.
…
-
Business21 hours agoMacquarie tips 14% upside for this ASX tech stock
-
Noosa News17 hours agoWilliam Robinson dies aged 89
-
Business19 hours agoTop brokers name 3 ASX shares to buy today 27 August 2025
-
Business21 hours agoThis ASX 200 media stock is storming 7% higher to 52-week highs. Here’s why.